| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_995c71109762882f3cc26e74d8d61acf |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16234
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55511
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-145 |
| filingDate |
2006-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2012-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f572a3dfdb4bfe4b22b391624ecd0405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4efde76d86ec1dd6deb34220c6f306cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8b50b167a8704c3e23e99cee826891d |
| publicationDate |
2012-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2377884-T3 |
| titleOfInvention |
Flu vaccines that include combinations of particulate adjuvants and immunopotentiators |
| abstract |
An immunogenic composition comprising: (i) an influenza virus antigen that is an inactivated virus and comprises complete viruses, fractionated viruses or purified surface antigens, or is in the form of virosomes; (ii) an insoluble particulate adjuvant comprising a microparticle prepared from poly (lactide-coglycolide); and (iii) an immunopotentiator that is an immunostimulatory oligonucleotide. |
| priorityDate |
2005-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |